Iridex/Miravant PDT For Macular Degeneration Granted FDA Expedited Review
This article was originally published in The Gray Sheet
Executive Summary
Miravant Medical Technologies and Iridex Corp. are seeking a broader indication for their photodynamic therapy laser than current offerings to treat age-related macular degeneration (AMD)
You may also be interested in...
Guidant Strengthens Resolve To Build Vulnerable Plaque Market
Guidant is backing its previously stated pledge to develop a market for the diagnosis and treatment of vulnerable plaque, investing in Miravant Medical Technologies' PhotoPoint photodynamic therapy
Guidant Strengthens Resolve To Build Vulnerable Plaque Market
Guidant is backing its previously stated pledge to develop a market for the diagnosis and treatment of vulnerable plaque, investing in Miravant Medical Technologies' PhotoPoint photodynamic therapy
Off-Label Photodynamic Therapy Coverage Extended To AMD Population
Clinical trial subgroup analyses showing the ability of lesion size to predict patient benefit helped convince CMS to expand national Medicare coverage of QLT/Novartis' Visudyne (verteporfin)